MIMIC-armored CAR T cells

MIMIC-armored CAR T cells are an experimental class of engineered cell therapies developed by Enoda Cellworks using their proprietary MIMIC (synthetic cytokine receptor) platform. These cells are engineered with synthetic receptors that graft signaling domains from cytokine receptors onto domains responsive to safe, orthogonal inputs, such as small molecules or antigen engagement, rather than endogenous ligands. This design decouples therapeutic signaling from the immunosuppressive tumor microenvironment (TME), allowing the CAR T cells to maintain expansion and effector function despite the presence of inhibitory factors like PD-1, TGF-β, adenosine, and PGE2. In preclinical models of hepatocellular carcinoma, GPC3-targeted CAR T cells armored with MIMIC signals demonstrated superior tumor control and survival compared to unarmored or dominant-negative TGF-β receptor-armored cells, even at lower infused doses.

Other names

MIMIC-armored CAR T cellsMIMIC-armored GPC3-CAR T cells